Elanco Animal Health Incorporated (NYSE:ELAN) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, seven have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $23.7778.

A number of research firms have weighed in on ELAN. Barclays started coverage on Elanco Animal Health in a report on Tuesday, December 9th. They set an “overweight” rating and a $30.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Elanco Animal Health in a research note on Monday. JPMorgan Chase & Co. upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $18.00 to $24.00 in a research note on Tuesday, October 7th. UBS Group lifted their price objective on Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Finally, Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 20th.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The stock was acquired at an average cost of $21.30 per share, with a total value of $213,000.00. Following the completion of the purchase, the director directly owned 131,773 shares in the company, valued at approximately $2,806,764.90. This represents a 8.21% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jeffrey N. Simmons acquired 22,000 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average price of $21.75 per share, with a total value of $478,500.00. Following the acquisition, the chief executive officer directly owned 167,000 shares of the company’s stock, valued at $3,632,250. The trade was a 15.17% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders acquired 43,450 shares of company stock worth $937,883. 0.89% of the stock is owned by insiders.

Institutional Trading of Elanco Animal Health

Several institutional investors and hedge funds have recently bought and sold shares of ELAN. SJS Investment Consulting Inc. increased its position in Elanco Animal Health by 2,563.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after buying an additional 1,333 shares in the last quarter. Huntington National Bank grew its stake in Elanco Animal Health by 136.7% in the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after acquiring an additional 1,087 shares during the period. Whittier Trust Co. of Nevada Inc. grew its stake in Elanco Animal Health by 80.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after acquiring an additional 900 shares during the period. Farther Finance Advisors LLC increased its holdings in shares of Elanco Animal Health by 79.3% during the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock valued at $43,000 after acquiring an additional 951 shares in the last quarter. Finally, Fifth Third Bancorp raised its position in shares of Elanco Animal Health by 3,018.3% during the third quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock worth $58,000 after purchasing an additional 2,807 shares during the period. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Performance

ELAN stock opened at $22.38 on Friday. The firm has a 50 day moving average of $22.07 and a two-hundred day moving average of $18.58. Elanco Animal Health has a 12 month low of $8.02 and a 12 month high of $23.70. The company has a market capitalization of $11.12 billion, a price-to-earnings ratio of 373.06, a P/E/G ratio of 3.42 and a beta of 1.86. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the prior year, the firm earned $0.13 EPS. Elanco Animal Health’s quarterly revenue was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. As a group, equities analysts anticipate that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.